Organoids to Study Intestinal Nutrient Transport, Drug Uptake and Metabolism – Update to the Human Model and Expansion of Applications

Intestinal transport and sensing processes and their interconnection to metabolism are relevant to pathologies such as malabsorption syndromes, inflammatory diseases, obesity and type 2 diabetes. Constituting a highly selective barrier, intestinal epithelial cells absorb, metabolize, and release nutrients into the circulation, hence serving as gatekeeper of nutrient availability and metabolic health for the whole organism. Next to nutrient transport and sensing functions, intestinal transporters including peptide transporter 1 (PEPT1) are involved in the absorption of drugs and prodrugs, including certain inhibitors of angiotensin-converting enzyme, protease inhibitors, antivirals, and peptidomimetics like β-lactam antibiotics. Here, we verify the applicability of 3D organoids for in vitro investigation of intestinal biochemical processes related to transport and metabolism of nutrients and drugs. Establishing a variety of methodologies including illustration of transporter-mediated nutrient and drug uptake and metabolomics approaches, we highlight intestinal organoids as robust and reliable tool in this field of research. Currently used in vitro models to study intestinal nutrient absorption, drug transport and enterocyte metabolism, such as Caco-2 cells or rodent explant models are of limited value due to their cancer and non-human origin, respectively. Particularly species differences result in poorly correlative data and findings obtained in these models cannot be extrapolated reliably to humans, as indicated by high failure rates in drug development pipelines. In contrast, human intestinal organoids represent a superior model of the intestinal epithelium and might help to implement the 3Rs (Reduction, Refinement and Replacement) principle in basic science as well as the preclinical and regulatory setup.

[1]  V. Lauschke,et al.  The past, present and future of intestinal in vitro cell systems for drug absorption studies. , 2020, Journal of pharmaceutical sciences.

[2]  H. Clevers,et al.  Human Organoids: Tools for Understanding Biology and Treating Diseases. , 2020, Annual review of pathology.

[3]  L. Fricker Proteasome Inhibitor Drugs. , 2020, Annual review of pharmacology and toxicology.

[4]  L. Sibley,et al.  Long-Term Culture Captures Injury-Repair Cycles of Colonic Stem Cells , 2019, Cell.

[5]  G. Bánhegyi,et al.  Species-Specific Glucose-6-Phosphatase Activity in the Small Intestine—Studies in Three Different Mammalian Models , 2019, International journal of molecular sciences.

[6]  Ömer H. Yilmaz,et al.  Gut Organoids: Mini-Tissues in Culture to Study Intestinal Physiology and Disease. , 2019, American journal of physiology. Cell physiology.

[7]  K. Faber,et al.  Corrigendum: Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases , 2019, Front. Immunol..

[8]  M. Inoue,et al.  Application of Cancer Organoid Model for Drug Screening and Personalized Therapy , 2019, Cells.

[9]  C. Kuo,et al.  Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions , 2019, Cell reports.

[10]  R. Damoiseaux,et al.  A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids , 2019, Communications Biology.

[11]  Toshio Takahashi,et al.  Organoids for Drug Discovery and Personalized Medicine. , 2019, Annual review of pharmacology and toxicology.

[12]  K. S. Kim,et al.  Microbiota-Derived Lactate Accelerates Intestinal Stem-Cell-Mediated Epithelial Development. , 2018, Cell host & microbe.

[13]  H. Kessler,et al.  Orally Active Peptides: Is There a Magic Bullet? , 2018, Angewandte Chemie.

[14]  F. Kastrinos,et al.  The Role of Genetics in Pancreatitis. , 2018, Gastrointestinal endoscopy clinics of North America.

[15]  M. Magnuson,et al.  Cytosolic phosphoenolpyruvate carboxykinase as a cataplerotic pathway in the small intestine. , 2018, American journal of physiology. Gastrointestinal and liver physiology.

[16]  W. Langhans,et al.  Enhancing enterocyte fatty acid oxidation in mice affects glycemic control depending on dietary fat , 2018, Scientific Reports.

[17]  H. Kessler,et al.  Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. , 2018, Molecular pharmaceutics.

[18]  R. Lindeboom,et al.  Integrative multi‐omics analysis of intestinal organoid differentiation , 2018, Molecular systems biology.

[19]  J. Pippin,et al.  Animal Research for Type 2 Diabetes Mellitus, Its Limited Translation for Clinical Benefit, and the Way Forward , 2018, Alternatives to laboratory animals : ATLA.

[20]  E. Novellino,et al.  Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3. , 2017, Angewandte Chemie.

[21]  M. Schwaiger,et al.  Exploring the Role of RGD-Recognizing Integrins in Cancer , 2017, Cancers.

[22]  Flavio Ballante,et al.  Limiting Assumptions in the Design of Peptidomimetics , 2017, Drug development research.

[23]  V. M. D. Martins dos Santos,et al.  Predicting the murine enterocyte metabolic response to diets that differ in lipid and carbohydrate composition , 2017, Scientific Reports.

[24]  H. Clevers,et al.  Organoid culture systems to study host–pathogen interactions , 2017, Current Opinion in Immunology.

[25]  Horst Kessler,et al.  Improving oral bioavailability of cyclic peptides by N-methylation. , 2017, Bioorganic & medicinal chemistry.

[26]  Qing-Yu Zhang,et al.  An update on the role of intestinal cytochrome P450 enzymes in drug disposition , 2016, Acta pharmaceutica Sinica. B.

[27]  H. Walles,et al.  Development of an Advanced Primary Human In Vitro Model of the Small Intestine. , 2016, Tissue engineering. Part C, Methods.

[28]  Asher Mullard,et al.  Parsing clinical success rates , 2016, Nature Reviews Drug Discovery.

[29]  Tamara Zietek,et al.  Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 , 2016, Front. Immunol..

[30]  Olga Kovbasnjuk,et al.  Human Enteroids as a Model of Upper Small Intestinal Ion Transport Physiology and Pathophysiology. , 2016, Gastroenterology.

[31]  Amin Rostami-Hodjegan,et al.  In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition , 2016, Drug Metabolism and Disposition.

[32]  K. Ebert,et al.  Fructose malabsorption , 2016, Molecular and Cellular Pediatrics.

[33]  Dudley Lamming,et al.  High fat diet enhances stemness and tumorigenicity of intestinal progenitors , 2016, Nature.

[34]  H. Daniel,et al.  Taste and move: glucose and peptide transporters in the gastrointestinal tract , 2015, Experimental physiology.

[35]  H. Daniel,et al.  Intestinal organoids for assessing nutrient transport, sensing and incretin secretion , 2015, Scientific Reports.

[36]  Marion P G Koopmans,et al.  Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. , 2015, Antiviral research.

[37]  K. Clément,et al.  Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. , 2015, Cell metabolism.

[38]  H. Daniel,et al.  Intestinal nutrient sensing and blood glucose control , 2015, Current opinion in clinical nutrition and metabolic care.

[39]  A. Kovar,et al.  Metabolism and disposition of the αv‐integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans , 2015, Journal of clinical pharmacology.

[40]  S. Kliewer,et al.  Bile Acids as Hormones: The FXR-FGF15/19 Pathway , 2015, Digestive Diseases.

[41]  E. Oki,et al.  SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer , 2015, Molecular Cancer Research.

[42]  Barbara M. Bakker,et al.  Short-Chain Fatty Acids Protect Against High-Fat Diet–Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation , 2015, Diabetes.

[43]  H. Clevers,et al.  Targeting development of incretin-producing cells increases insulin secretion. , 2015, The Journal of clinical investigation.

[44]  J. Segain,et al.  Connecting metabolism to intestinal barrier function: The role of leptin , 2014, Tissue barriers.

[45]  H. Miyoshi,et al.  Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays , 2014, Gut.

[46]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[47]  M. Leist,et al.  Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy , 2014, Cell Death and Disease.

[48]  Hans Clevers,et al.  Adult Stem Cells in the Small Intestine Are Intrinsically Programmed with Their Location‐Specific Function , 2014, Stem cells.

[49]  H. Daniel,et al.  The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing , 2014, PloS one.

[50]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[51]  H. Daniel,et al.  Peptide transporter isoforms are discriminated by the fluorophore‐conjugated dipeptides β‐Ala‐ and d‐Ala‐Lys‐N‐7‐amino‐4‐methylcoumarin‐3‐acetic acid , 2013, Physiological reports.

[52]  R. Wanders,et al.  Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. , 2013, Biochimica et biophysica acta.

[53]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[54]  B. Brodin,et al.  Basolateral glycylsarcosine (Gly‐Sar) transport in Caco‐2 cell monolayers is pH dependent , 2013, The Journal of pharmacy and pharmacology.

[55]  W. Langhans,et al.  Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats[S] , 2013, Journal of Lipid Research.

[56]  A. Wali,et al.  Microbial Regulation of Glucose Metabolism and Cell-Cycle Progression in Mammalian Colonocytes , 2012, PloS one.

[57]  W. de Lau,et al.  Peyer's Patch M Cells Derived from Lgr5+ Stem Cells Require SpiB and Are Induced by RankL in Cultured “Miniguts” , 2012, Molecular and Cellular Biology.

[58]  Dudley Lamming,et al.  mTORC1 in the Paneth cell niche couples intestinal stem cell function to calorie intake , 2012, Nature.

[59]  J. Arrowsmith,et al.  A decade of change , 2012, Nature Reviews Drug Discovery.

[60]  J. Minna,et al.  SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner. , 2011, Cancer research.

[61]  H. Kessler,et al.  The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. , 2011, Molecular pharmaceutics.

[62]  W. Langhans,et al.  Dietary fat sensing via fatty acid oxidation in enterocytes: possible role in the control of eating. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[63]  Horst Kessler,et al.  Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.

[64]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[65]  H. Daniel,et al.  Gene ablation for PEPT1 in mice abolishes the effects of dipeptides on small intestinal fluid absorption, short-circuit current, and intracellular pH. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[66]  G. Cresci,et al.  Colonic Gene Expression in Conventional and Germ-Free Mice with a Focus on the Butyrate Receptor GPR109A and the Butyrate Transporter SLC5A8 , 2010, Journal of Gastrointestinal Surgery.

[67]  B. Thorens,et al.  Glucose transporters in the 21st Century. , 2010, American journal of physiology. Endocrinology and metabolism.

[68]  Patrick J. Lindsey,et al.  Butyrate-Induced Transcriptional Changes in Human Colonic Mucosa , 2009, PloS one.

[69]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[70]  A. Leturque,et al.  Sugar absorption in the intestine: the role of GLUT2. , 2008, Annual review of nutrition.

[71]  Takahiko Nakagawa,et al.  Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. , 2007, The American journal of clinical nutrition.

[72]  Ulf Norinder,et al.  Exploring the role of different drug transport routes in permeability screening. , 2005, Journal of medicinal chemistry.

[73]  A. Munnich,et al.  Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. , 2004, Molecular aspects of medicine.

[74]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[75]  Marival Bermejo,et al.  PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[76]  H. Daniel,et al.  PEPT1-Mediated Cefixime Uptake into Human Intestinal Epithelial Cells Is Increased by Ca2+ Channel Blockers , 2002, Antimicrobial Agents and Chemotherapy.

[77]  U. Hopfer,et al.  Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[78]  K. Nair,et al.  The effect of insulin on human small intestinal mucosal protein synthesis. , 2000, Gastroenterology.

[79]  S. Grinstein,et al.  Selective inhibition of the Na+/H+ exchanger type 3 activates CO2/H+-sensitive medullary neurones , 1999, Pflügers Archiv.

[80]  D. Fleisher,et al.  Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers , 1999, Pharmaceutical Research.

[81]  R. Santer,et al.  Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome , 1997, Nature Genetics.

[82]  Shiyin Yee,et al.  In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.

[83]  Morton B. Brown,et al.  Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.

[84]  E. Wright,et al.  Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption , 1996, Nature Genetics.

[85]  V. Ganapathy,et al.  Differential Recognition of β-Lactam Antibiotics by Intestinal and Renal Peptide Transporters, PEPT 1 and PEPT 2 (*) , 1995, The Journal of Biological Chemistry.

[86]  Thomas Kolter,et al.  Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives , 1993 .

[87]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[88]  S. Gumina,et al.  The Role of Genetics , 2017 .

[89]  S. Shuto,et al.  Conjugation of dipeptide to fluorescent dyes enhances its affinity for a dipeptide transporter (PEPT1) in human intestinal Caco-2 cells. , 1999, Bioconjugate chemistry.

[90]  M. Pinto,et al.  Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture , 1983 .